Inventor
LOEW ANDREAS
US65 patents
⚠️ This page may combine multiple inventors who share the name “LOEW ANDREAS”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
NOVARTIS AG
21 patentsUS10221245B2Mar 5, 2019
Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
NOVARTIS AG36 citations94
US10253086B2Apr 9, 2019
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
NOVARTIS AG37 citations93
US10287354B2May 14, 2019
Regulatable chimeric antigen receptor
NOVARTIS AG29 citations92
US9458214B2Oct 4, 2016
Dual function fibroblast growth factor 21 proteins
NOVARTIS AG15 citations90
US10927184B2Feb 23, 2021
Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
NOVARTIS AG10 citations86
US11149076B2Oct 19, 2021
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
NOVARTIS AG9 citations84
US8883735B2Nov 11, 2014
Low density lipoprotein-related protein 6 (LRP6)-half life extender constructs
NOVARTIS AG8 citations84
US10640569B2May 5, 2020
Human mesothelin chimeric antigen receptors and uses thereof
NOVARTIS AG15 citations83
US10308717B2Jun 4, 2019
Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
NOVARTIS AG4 citations83
US10577417B2Mar 3, 2020
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
NOVARTIS AG10 citations82
US12344657B2Jul 1, 2025
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
NOVARTIS AG1 citations73
US11028177B2Jun 8, 2021
Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
NOVARTIS AG4 citations73
US11865167B2Jan 9, 2024
Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
NOVARTIS AG2 citations72
US11542488B2Jan 3, 2023
Sortase synthesized chimeric antigen receptors
NOVARTIS AG2 citations71
US9173960B2Nov 3, 2015
Methods of treating cancer with low density lipoprotein-related protein 6 (LRP6)—half life extender constructs
NOVARTIS AG2 citations63
US12559562B2Feb 24, 2026
Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
NOVARTIS AG0 citations62
US11591404B2Feb 28, 2023
Treatment of cancer using a CD123 chimeric antigen receptor
NOVARTIS AG0 citations62
US10703819B2Jul 7, 2020
Treatment of cancer using a CD123 chimeric antigen receptor
NOVARTIS AG1 citations62
US11578130B2Feb 14, 2023
Regulatable chimeric antigen receptor
NOVARTIS AG1 citations61
US11999794B2Jun 4, 2024
Human mesothelin chimeric antigen receptors and uses thereof
NOVARTIS AG0 citations60
US11981731B2May 14, 2024
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
NOVARTIS AG0 citations60
MARENGO THERAPEUTICS INC
11 patentsUS11291721B2Apr 5, 2022
Multispecific and multifunctional molecules and uses thereof
MARENGO THERAPEUTICS INC15 citations85
US11965025B2Apr 23, 2024
Method of treating solid cancers with bispecific interleukin-anti-TCRß molecules
MARENGO THERAPEUTICS INC7 citations83
US11845797B2Dec 19, 2023
Anti-TCR antibody molecules and uses thereof
MARENGO THERAPEUTICS INC7 citations83
US12351632B2Jul 8, 2025
Anti-TCR antibody molecules and uses thereof
MARENGO THERAPEUTICS INC1 citations72
US12286477B2Apr 29, 2025
Anti-TCR antibody molecules and uses thereof
MARENGO THERAPEUTICS INC1 citations72
US12152073B2Nov 26, 2024
Multifunctional molecules that bind to calreticulin and uses thereof
MARENGO THERAPEUTICS INC4 citations66
US12247060B2Mar 11, 2025
Calreticulin binding constructs and engineered T cells for the treatment of diseases
MARENGO THERAPEUTICS INC1 citations63
US12486326B2Dec 2, 2025
Anti-TCR antibody molecules and uses thereof
MARENGO THERAPEUTICS INC1 citations60
US12421323B2Sep 23, 2025
Multispecific antibody molecules comprising lambda and kappa light chains
MARENGO THERAPEUTICS INC0 citations59
US11673971B2Jun 13, 2023
Multispecific antibody molecules comprising lambda and kappa light chains
MARENGO THERAPEUTICS INC1 citations59
US12384842B2Aug 12, 2025
Antibody molecules that bind to NKP30 and uses thereof
MARENGO THERAPEUTICS INC1 citations58
THOMSON LICENSING
5 patentsUS7508435B2Mar 24, 2009
Method for the correction of video signals
THOMSON LICENSING9 citations81
US7565031B2Jul 21, 2009
Method and circuit for scaling raster images
THOMSON LICENSING6 citations63
US7444020B2Oct 28, 2008
Reduction of rounding errors during the processing of digital image data
THOMSON LICENSING3 citations63
US7262833B2Aug 28, 2007
Circuit for addressing a memory
THOMSON LICENSING2 citations63
US7248747B2Jul 24, 2007
Method and arrangement for the correction of video signals
THOMSON LICENSING2 citations63
BROGDON JENNIFER
3 patentsUS9815901B2Nov 14, 2017
Treatment of cancer using a CD123 chimeric antigen receptor
BROGDON JENNIFER94 citations97
US9573988B2Feb 21, 2017
Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
BROGDON JENNIFER87 citations97
US9394368B2Jul 19, 2016
Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
BROGDON JENNIFER112 citations97
LOEW ANDREAS
3 patentsBOETTCHER BRIAN R
2 patentsPHILIPS CORP
1 patentCONG FENG
1 patentNUANCE COMMUNICATIONS INC
1 patentKOENIG LARS
1 patentBROADCAST TELEVISION SYST
1 patentShowing the top 50 of 65 patents by PatentIndex Score.